Martijn J W Evers
Overview
Explore the profile of Martijn J W Evers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bevers S, Kooijmans S, Van de Velde E, Evers M, Seghers S, Gitz-Francois J, et al.
Mol Ther
. 2022 Jul;
30(9):3078-3094.
PMID: 35821637
mRNA vaccines have recently proved to be highly effective against SARS-CoV-2. Key to their success is the lipid-based nanoparticle (LNP), which enables efficient mRNA expression and endows the vaccine with...
2.
Evers M, Du W, Yang Q, Kooijmans S, Vink A, van Steenbergen M, et al.
J Control Release
. 2022 Jan;
343:207-216.
PMID: 35077739
Lipid Nanoparticles (LNPs) are a promising drug delivery vehicle for clinical siRNA delivery. Modified mRNA (modRNA) has recently gained great attention as a therapeutic molecule in cardiac regeneration. However, for...
3.
Evers M, van de Wakker S, de Groot E, de Jong O, Gitz-Francois J, Seinen C, et al.
Adv Healthc Mater
. 2021 Aug;
11(5):e2101202.
PMID: 34382360
The therapeutic use of RNA interference is limited by the inability of siRNA molecules to reach their site of action, the cytosol of target cells. Lipid nanoparticles, including liposomes, are...
4.
Murphy D, de Jong O, Evers M, Nurazizah M, Schiffelers R, Vader P
Nano Lett
. 2021 Feb;
21(4):1888-1895.
PMID: 33570966
RNA therapeutics have high potential that is yet to be fully realized, largely due to challenges involved in the appropriate delivery to target cells. Extracellular vesicles (EVs) are lipid bound...
5.
Aldosari M, den Hartog M, Ganizada H, Evers M, Mastrobattista E, Schellekens H
Curr Pharm Biotechnol
. 2020 Feb;
21(6):467-479.
PMID: 32065100
Objective: The high cost of orphan drugs limits their access by many patients, especially in low- and middle-income countries. Many orphan drugs are off-patent without alternative generic or biosimilar versions...
6.
de Jong O, Kooijmans S, Murphy D, Jiang L, Evers M, Sluijter J, et al.
Acc Chem Res
. 2019 Jun;
52(7):1761-1770.
PMID: 31181910
Extracellular vesicles are nanoparticles produced by cells. They are composed of cellular membrane with associated membrane proteins that surrounds an aqueous core containing soluble molecules such as proteins and nucleic...
7.
Critical evaluation of quantification methods for oligonucleotides formulated in lipid nanoparticles
Oude Blenke E, Evers M, Baumann V, Winkler J, Storm G, Mastrobattista E
Int J Pharm
. 2017 Dec;
548(2):793-802.
PMID: 29275035
There is a very large variety in the types of nanoparticulate lipid formulations for oligonucleotides, and remarkably, also a very large heterogeneity in the methods that are used for analyzing...
8.
Oude Blenke E, Evers M, Mastrobattista E, van der Oost J
J Control Release
. 2016 Aug;
244(Pt B):139-148.
PMID: 27498021
The CRISPR-Cas9 gene editing system has taken the biomedical science field by storm, initiating rumors about future Nobel Prizes and heating up a fierce patent war, but also making significant...